Phase-III trials of the Covaxin vaccine from India's Bharat Biotech showed a 65.2% efficacy against the Delta variant, a 77.8% efficacy against symptomatic COVID-19, and a 93.4% efficacy against severe COVID-19.
Phase-III trials of Covaxin from India's Bharat Biotech showed 65.2% efficacy against the Delta variant, 77.8% efficacy against symptomatic COVID-19, and 93.4% efficacy against severe COVID-19.
Phase-III trials of theCovaxin vaccinefrom India's Bharat Biotech showed a65.2% efficacy against the Delta variant, a77.8% efficacy against symptomatic COVID-19, anda 93.4% efficacy against severe COVID-19.
